Tianeptine: An Atypical Antidepressant with Multimodal Pharmacology
Summary (3 min read)
1. Introduction
- Major depressive disorder (MDD) is a highly pervasive disorder, characterised by persistent low mood, low self-esteem and anhedonia.
- In the UK, depression affects 4 million adults, 8.4% of the total population and has been linked with poor health, significant comorbidity and mortality [1-3].
- MDD, therefore, is characterised as a severely debilitating disease with a major impact not only on a person's quality of life but can also place a massive financial strain on a country’s healthcare system.
- All four classes of antidepressants have proven to be catalysts by dramatically improving the quality of life of depressed patients [4].
- These agents, however, are associated with limitations in their onset of action, efficacy, tolerability and safety.
2. Clinical Efficacy of Tianeptine
- The authors have attempted a comprehensive review of all the accessible clinical trial information on tianeptine and their findings are summarized in Table 1.
- In one study, 286 adult patients of both genders were treated with tianeptine for 6 weeks [16].
- Clinical evidence also supports an improvement in cognitive function following treatment with tianeptine.
- There is also strong clinical evidence that tianeptine is beneficial for overcoming treatmentresistant depression when combined with other antidepressants [27-28].
- Patients were diagnosed with MDD and did not respond or partially responded to SSRI monotherapy [27].
2.1 Safety and Tolerability of Tianeptine
- A number of safety studies from various clinical trials have described tianeptine as a welltolerated drug.
- Tianeptine’s safety credentials are furthermore enhanced by the fact that it has a very low overdose risk, therefore, has been classed as a drug with a low abuse potential.
- Undoubtedly, one of the major drawbacks of current antidepressant treatments is the discontinuation symptoms that occur after cessation of treatment.
- Antidepressant therapy is clinically proven to aggravate such problems; results from the same study revealed that patients on antidepressants increased the frequency of sexual dysfunction compared to the untreated patients [35].
- In comparison with TCAs and SSRIs, tianeptine exhibited a lower incidence of sexual dysfunction having a similar rate of untreated patients [35].
3.1 Brain Structure and Neurotrophic Effects
- Neuroplasticity is the ability of the adult and differentiated brain to adapt functionally and structurally to internal and external stimuli [37].
- Specifically, a study involving 16 patients with depression revealed that in all cases the volume of the left side of the hippocampus was 19% smaller when compared to 16 nondepressed patients [41].
- 2 Synaptic Plasticity Synaptic plasticity is the ability of neurones to undergo activity-dependent alterations in synaptic function in order to determine how the synapse will respond to afferent activity [48].
- More specifically the use of animal models has revealed that acute and chronic stress inhibits the ability of the hippocampus and the prefrontal cortex to undergo long-term potentiation (LTP) [50-51].
- Tianeptine (10mg/kg) successfully enhanced synaptic function in the hippocampus [52-53] and prefrontal cortex [53] while maintaining normal synaptic function in the amygdala [54] of male Sprague-Dawley rats; the potentiation of LTP was reported to occur immediately after tianeptine administration.
3.3 Memory and Cognition
- A functional consequence of MDD and stress involves impairment of cognitive and memory function.
- Impairment in memory function is believed to occur due to damage to the hippocampus by stress and its related hormones [50, 55]; particularly damage in the region is associated with altered spatial memory.
- Fascinatingly, evidence from the same experiment suggests that tianeptine improves memory without affecting the stress-induced rise in glucocorticoid suggesting that tianeptine does not interfere with activation of the hypothalamic-pituitary-adrenal axis following stress [56].
- These effects of tianeptine are consistent with findings obtained from adrenalectomised rats [55].
- During MDD the amygdala is thought to be dysregulated, with fear-related learning being impaired [57-58].
4.1 Actions at the Serotonin Reuptake Transporter
- One molecular target of tianeptine is the serotonin reuptake transporter (SERT) – a transporter which mediates reuptake of serotonin in neurones [62].
- SSRIs have been proposed to inhibit SERT by interacting with the C-terminal part of SERT containing the transmembrane domains 10 and 12; specifically they form dipole-dipole interactions or hydrogen bonds with the benzene ring of the Tyr95 and make the transporter adopt a conformation that decreases the affinity for serotonin or reduces its rate of transport [62-63].
- Similarly to other classes of antidepressant, tianeptine was anticipated to interfere with neurotransmission of the serotonin system, due to its apparent mechanism of action.
- Initially, this notion was shown to be true by experiments that revealed that acute and sustained administration of tianeptine (10mg/kg) decreased the synaptic availability of serotonin in rat brains [66, 68].
- The validity of these studies has been questioned due to the technical limitations that could not be avoided at the time [70].
4.3 Interactions with -receptors
- Clinically, recommended dosing with tianeptine is 37.5 mg/day.
- These effects were independent of any serotonin mediated actions of tianeptine [109] and could account for the apparent abuse and dependency seen at higher doses of tianeptine.
- These authors suggested that the high dose tianeptine and amitriptyline interacted with opioid receptors since naloxone effectively reversed these effects.
- Activation of both - and -receptors could also contribute to the antidepressant actions of tianeptine.
5. Pharmacokinetics of Tianeptine
- In healthy individuals, the pharmacokinetic properties of tianeptine have been extensively studied.
- Only MC5 is known to possess pharmacological activity [124].
- Taking into account the pivotal role of the kidneys in the clearance of tianeptine, individuals with impaired kidney function exhibit altered tianeptine pharmacokinetic properties.
- Moreover, there seems to be a dramatic heightening of the terminal half-life of the metabolite MC5 in patients with renal failure [124].
- Tianeptine has been associated with gender-specific differences in efficacy which may be attributable to gender differences in pharmacokinetics.
6. Conclusion
- Clinically tianeptine is as efficacious as SSRIs with more rapid improvements in cognitive function and anxiety relieving properties.
- What is more, in terms of safety and tolerability tianeptine is particularly attractive since clinical studies have shown it to be less hazardous and significantly less prone to disrupting the patient’s normal functionality.
- Tianeptine is an atypical antidepressant acting at SERT to stimulate serotonin reuptake, although this mechanism is unlikely to explain tianeptine’s antidepressant properties.
- One more plausible mechanism by which tianeptine produces its antidepressant and neurorestorative properties is via modulation of the glutamatergic system which is achieved by an effect upon the glycine site of the NMDA receptor; inhibiting its function, and mTOR signalling by indirectly enhancing AMPA-related signalling.
- Tianeptine itself is off patent, but it still holds much promise as an experimental tool, yielding valuable insights into the molecular mechanisms underlying depression.
Did you find this useful? Give us your feedback
Citations
12 citations
10 citations
2 citations
2 citations
References
241 citations
"Tianeptine: An Atypical Antidepress..." refers background in this paper
...In more detail, administration of tianeptine (10mg/kg) reduced auditory fear conditioning in rats; the authors report that these effects of tianeptine are observed after long-term administration and not acutely [61]....
[...]
240 citations
"Tianeptine: An Atypical Antidepress..." refers background in this paper
...Specifically, it is hypothesised that the amygdala exhibits potentiation of synaptic function and LTP during intense emotional experiences [59-60] resulting in amplification of fearrelated behaviour....
[...]
...Tianeptine (10mg/kg) successfully enhanced synaptic function in the hippocampus [52-53] and prefrontal cortex [53] while maintaining normal synaptic function in the amygdala [54] of male Sprague-Dawley rats; the potentiation of LTP was reported to occur immediately after tianeptine administration....
[...]
...Tianeptine had no impact on amplification of LTP in the basolateral nucleus of the amygdala following a stressful stimulus [54]....
[...]
...Interestingly tianeptine reversed the inhibitory effects of stress on LTP and mediated generation of a form of low threshold potentiation known as burst potentiation (PBP) [53-54]; priming of PBP was independent of stress experience....
[...]
...More specifically the use of animal models has revealed that acute and chronic stress inhibits the ability of the hippocampus and the prefrontal cortex to undergo long-term potentiation (LTP) [50-51]....
[...]
232 citations
"Tianeptine: An Atypical Antidepress..." refers background or result in this paper
...Antidepressant therapy is clinically proven to aggravate such problems; results from the same study revealed that patients on antidepressants increased the frequency of sexual dysfunction compared to the untreated patients [35]....
[...]
...In comparison with TCAs and SSRIs, tianeptine exhibited a lower incidence of sexual dysfunction having a similar rate of untreated patients [35]....
[...]
...A French study involving 4557 outpatients concluded that the prevalence of sexual dysfunction was 35% for spontaneously reported problems and 69% for problems identified by physician questioning [35]....
[...]
229 citations
224 citations